|
Re: Evacetrapib fails
|
4
|
Resverlogix Corp.
|
May 18, 2017 11:02AM
|
|
Re: ... have you taken notice?...
|
4
|
Resverlogix Corp.
|
Apr 25, 2016 07:34AM
|
|
Re: Buyout?......
|
4
|
Resverlogix Corp.
|
Jun 02, 2019 10:07PM
|
|
Re: HDL from an Alzheimer's disease perspective
|
4
|
Resverlogix Corp.
|
Jun 27, 2019 11:59AM
|
|
Prostate Cancer Foundation Retreat 2019 - Poster
|
4
|
Zenith Epigenetics
|
Oct 31, 2019 02:58PM
|
|
CTAD Twitter Exchange
|
4
|
Resverlogix Corp.
|
Nov 02, 2019 11:57AM
|
|
Re: ZEN-3694 Single Agent Trial Status
|
4
|
Zenith Epigenetics
|
Jul 14, 2017 03:26PM
|
|
Re: FDA approves drug that reduces MACE in Diabetes patients (Forbes)
|
4
|
Resverlogix Corp.
|
Jun 14, 2016 11:01AM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
4
|
Resverlogix Corp.
|
May 14, 2019 04:16PM
|
|
ESC Poster on Vascular Inflammation, Calcification and Plaque Vulnerability
|
4
|
Resverlogix Corp.
|
Sep 03, 2019 09:48AM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
4
|
Resverlogix Corp.
|
Dec 06, 2017 07:52PM
|
|
Re: Zenith AGM thoughts
|
4
|
Zenith Epigenetics
|
Nov 28, 2017 10:48PM
|
|
November conferences
|
4
|
Resverlogix Corp.
|
Oct 15, 2015 12:08PM
|
|
Re: New Zacks SCR report "Apabetalone: A Potential Alzheimer's Play?"
|
4
|
Resverlogix Corp.
|
Aug 26, 2018 10:57AM
|
|
Re: tiny volume
|
4
|
Resverlogix Corp.
|
Oct 03, 2018 05:01PM
|
|
Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications
|
3
|
BIOASIS TECHNOLOGIES INC
|
Jun 25, 2019 06:52AM
|
|
Re: AMRN Adcom
|
3
|
Resverlogix Corp.
|
Aug 08, 2019 09:40PM
|
|
Re: Just a guess on my part....
|
3
|
Resverlogix Corp.
|
May 09, 2018 04:46PM
|
|
Re: True to Your Heart
|
3
|
Resverlogix Corp.
|
Feb 25, 2020 10:36AM
|
|
Re: The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
|
3
|
Resverlogix Corp.
|
Sep 29, 2017 03:32PM
|
